What really works to prevent cognitive decline?
Journal of the American Medical Association offers additional support for intensive treatment of blood pressure in reducing the risk of developing mild cognitive impairment. Blood pressure is monitored by tracking two numbers, systolic over diastolic. For example, 135/87. Systolic pressure is the first number in the pair. Intensive treatment of blood pressure means shooting for a target number of 120 or lower for the systolic blood pressure reading.
Meanwhile, while watching the news you see advertisements for supplements to improve brain health and cognition. Something to do with jellyfish? If you want to spend some money you can buy proprietary supplement products with great names like Alpha Brain®, Qualia Mind or Bulletproof® brain octane oil. Numerous generic and widely available supplement ingredients have been touted as being brain-boosting or neuroprotective.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
'Grandfather of Climate Science' Wallace Broecker Dies at 87Broecker was an early advocate for reducing fossil fuels to avoid the disruptive effects of climate change and brought the term 'global warming' into the mainstream.
Consulte Mais informação »
Wallace Smith Broecker, 'Grandfather of Climate Science' who revealed global warming to public, dies at 87Broecker once said that by burning fossil fuels, we are “playing with an angry beast.”
Consulte Mais informação »
What Teachers Need To Know About The Science Of Learning--And What They Don'tLately there’s been a push to acquaint educators with “the science of learning.” But only some aspects of that science actually help teachers do their jobs. Others just waste their time.
Consulte Mais informação »
Achieve Life Sciences' stock rockets on heavy volume after update results of smoking-cessation drug trialShares of Achieve Life Sciences Inc. rocketed 73% to pace all premarket gainers in active trade Friday, after the company reported upbeat results from a trial of its smoking-cessation drug. Trading volume reached 1.8 million shares ahead of the open, compared with the full-day average of about 151,000 shares. The company said it evaluated repeat doses of cytisinicline in 26 healthy volunteer smokers, who smoked an average 17.2 cigarettes a day. By the 26th day of treatment, there was an averag80% reduction in cigarettes smoked, 82% reduction in expired carbon monoxide and 46% had stopped smoking. Cytisinicline was well tolerated, with only "transient, mild-to-moderate headache" as the most common adverse event. "Given the short 25-day treatment period, the abstinence rates observed are impressive, particularly since subjects were not required to commit to quitting and received minimal behavioral support during the study," said Chief Medical Officer Cindy Jacobs. The stock has tumbled 87% over the past 12 months through Thursday, while the S&P 500 has gained 2.6%.
Consulte Mais informação »